Attention Deficit Hyperactivity Disorder
📧 Sign up to get email alerts when something new happens for Attention Deficit Hyperactivity Disorder.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-02-25FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Granules Pharmaceuticals Inc.)
FDA approved a supplemental application for Amphetamine Sulfate submitted by Granules Pharmaceuticals Inc.
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Oryza Pharmaceuticals Inc.)
FDA approved a supplemental application for a generic mixed amphetamine salts product consisting of dextroamphetamine saccharate, amphetamin…
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE — Supplemental Application (Cranbury Pharmaceuticals, LLC)
The FDA approved Cranbury Pharmaceuticals' supplemental application for dextroamphetamine (generic) under ANDA 203644, enabling the generic …
-
FDA approval · 2022-02-25FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application from Sun Pharmaceutical to market a generic product containing a combination of dextroamphetamine an…
-
FDA approval · 2022-02-14FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's supplemental application to market a generic product containing four amphetamine salts (dextroamphetamine …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2022-02-14FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
The FDA granted supplemental approval for Teva Pharmaceuticals USA, Inc. to market a generic combination product containing four amphetamine…
-
FDA approval · 2022-02-14FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Supplemental Application (NorthStar RxLLC)
FDA approved a supplemental application for the combination of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfat…
-
FDA approval · 2022-02-10FDA Approved: AMPHETAMINE SULFATE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
FDA approved a supplemental application for Amphetamine Sulfate (amphetamine) by Amneal Pharmaceuticals NY LLC under ANDA211139, marking a r…
-
FDA approval · 2022-01-31FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE, AND AMPHETAMINE SULFATE — Original Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva's generic combination of four amphetamine salts (dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroam…
-
FDA approval · 2021-12-28FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Granules Pharmaceuticals Inc.)
FDA approved a new generic combination amphetamine product (dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, …
-
FDA approval · 2021-12-08FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic dexmethylphenidate hydrochloride as an original application, expanding access to ADHD treatment…
-
FDA approval · 2021-11-26FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Golden State Medical Supply, Inc.)
FDA approved a generic drug product comprising four amphetamine salts (dextroamphetamine sulfate, dextroamphetamine saccharate, amphetamine …
-
FDA approval · 2021-11-23FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE EXTENDED-RELEASE — Original Application (Par Health USA, LLC)
The FDA approved an extended-release dexmethylphenidate hydrochloride product from Par Health USA, LLC through an Original Application (ANDA…
-
FDA approval · 2021-11-04FDA Approved: DYANAVEL XR — Original Application (NextWave Pharmaceuticals, Inc)
FDA approves DYANAVEL XR under original NDA for the treatment of attention-deficit/hyperactivity disorder. The product is developed by NextW…
-
FDA approval · 2021-11-02FDA Approved: VYVANSE — Supplemental Application (Takeda Pharmaceuticals America, Inc.)
The FDA approved a supplemental application for Vyvanse (lisdexamfetamine dimesylate) submitted by Takeda Pharmaceuticals America, Inc.
-
FDA approval · 2021-11-01FDA Approved: DEXMETHYLPHENIDATE HYDROCHLORIDE — Supplemental Application (Par Health USA, LLC)
The FDA approved a supplemental application for dexmethylphenidate hydrochloride from Par Health USA, LLC. Dexmethylphenidate hydrochloride …
-
FDA approval · 2021-09-29FDA Approved: DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, DEXTROAMPHETAMINE SULFATE AND AMPHETAMINE SULFATE — Original Application (Camber Pharmaceuticals, Inc.)
FDA approved Camber Pharmaceuticals' generic product containing dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphe…
-
FDA approval · 2021-07-19FDA Approved: METHYLIN — Supplemental Application (SHIONOGI INC.)
FDA approved a supplemental application for MethyLin (methylphenidate hydrochloride) submitted by Shionogi under NDA 021419.
-
FDA approval · 2021-06-26FDA Approved: FOCALIN XR — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN XR (dexmethylphenidate hydrochloride) submitted by Sandoz Inc.
-
FDA approval · 2021-06-26FDA Approved: FOCALIN — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for FOCALIN (dexmethylphenidate hydrochloride) filed by Sandoz Inc.
-
FDA approval · 2021-06-26FDA Approved: METHYLPHENIDATE — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for methylphenidate submitted by Sandoz Inc.
-
FDA approval · 2021-06-25FDA Approved: METHYLPHENIDATE TRANSDERMAL SYSTEM — Supplemental Application (PADAGIS US LLC)
FDA approved a supplemental application for the Methylphenidate Transdermal System (methylphenidate patch) by PADAGIS US LLC. The product is…
-
FDA approval · 2021-06-25FDA Approved: METHYLPHENIDATE HYDROCHLORIDE CD — Supplemental Application (Lannett Company, Inc.)
The FDA approved a supplemental application for Methylphenidate Hydrochloride CD from Lannett Company, Inc. The approval indicates an update…
-
FDA approval · 2021-06-25FDA Approved: CONCERTA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for CONCERTA (methylphenidate hydrochloride) submitted by Janssen Pharmaceuticals, Inc. This act…
-
FDA approval · 2021-06-25FDA Approved: QUILLIVANT XR — Supplemental Application (NextWave Pharmaceuticals, Inc)
The FDA approved a supplemental application for QUILLIVANT XR (methylphenidate hydrochloride) submitted by NextWave Pharmaceuticals, Inc.